ATE309365T1 - Hiv-1 der gruppe 0, entsprechende fragmente dieses virus,sowie deren anwendungen - Google Patents

Hiv-1 der gruppe 0, entsprechende fragmente dieses virus,sowie deren anwendungen

Info

Publication number
ATE309365T1
ATE309365T1 AT96904904T AT96904904T ATE309365T1 AT E309365 T1 ATE309365 T1 AT E309365T1 AT 96904904 T AT96904904 T AT 96904904T AT 96904904 T AT96904904 T AT 96904904T AT E309365 T1 ATE309365 T1 AT E309365T1
Authority
AT
Austria
Prior art keywords
hiv
group
virus
applications
corresponding fragments
Prior art date
Application number
AT96904904T
Other languages
English (en)
Inventor
Francois Simon
Sentob Saragosti
Ibtissam Loussert-Ajaka
Thoai-Duong Ly
Marie-Laure Chaix-Baudier
Original Assignee
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE309365T1 publication Critical patent/ATE309365T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96904904T 1995-02-27 1996-02-26 Hiv-1 der gruppe 0, entsprechende fragmente dieses virus,sowie deren anwendungen ATE309365T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9502236A FR2731013B1 (fr) 1995-02-27 1995-02-27 Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
PCT/FR1996/000294 WO1996027013A1 (fr) 1995-02-27 1996-02-26 Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications

Publications (1)

Publication Number Publication Date
ATE309365T1 true ATE309365T1 (de) 2005-11-15

Family

ID=9476523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96904904T ATE309365T1 (de) 1995-02-27 1996-02-26 Hiv-1 der gruppe 0, entsprechende fragmente dieses virus,sowie deren anwendungen

Country Status (9)

Country Link
US (2) US6030769A (de)
EP (1) EP0812359B1 (de)
JP (1) JPH11501805A (de)
AT (1) ATE309365T1 (de)
CA (1) CA2214102C (de)
DE (1) DE69635407T2 (de)
ES (1) ES2256855T3 (de)
FR (1) FR2731013B1 (de)
WO (1) WO1996027013A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19505262C2 (de) * 1995-02-16 1998-06-18 Behring Diagnostics Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
FR2775287B1 (fr) * 1998-02-24 2000-11-24 Pasteur Sanofi Diagnostics Peptides synthetiques consensus utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 du groupe o
FR2761993B1 (fr) * 1997-04-09 1999-05-21 Pasteur Sanofi Diagnostics Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 groupe 0
CZ300927B6 (cs) 1997-04-09 2009-09-16 Bio-Rad Pasteur Syntetický peptid monomerního typu, prostredek, který ho obsahuje, zpusob imunologické in vitro kvantifikace a diagnostický kit pro použití v biologických testech pro identifikaci infekcí zpusobených viry HIV
AU754049B2 (en) * 1997-07-18 2002-10-31 Innogenetics N.V. HIV-1 group O antigens and uses thereof
AU2345399A (en) * 1998-01-28 1999-08-16 Universal Health-Watch, Inc. Divergent hiv-1 peptides
WO1999045395A1 (en) * 1998-03-04 1999-09-10 Universal Healthwatch, Inc. Rapid confirmatory test for microbial infections
WO1999062945A2 (en) * 1998-06-05 1999-12-09 Peptide Solutions, Inc. Peptide antigens for detection of hiv, hcv and other microbial infections
CA2676762C (en) * 1998-11-30 2015-12-29 Ortho-Clinical Diagnostics, Inc. Peptides for the detection of hiv-1 group o
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
WO2001004361A2 (en) 1999-07-09 2001-01-18 Gen-Probe Incorporated Detection of hiv-1 by nucleic acid amplification
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
FR2869045A1 (fr) * 2004-04-16 2005-10-21 Bioalliance Pharma Sa Methode d'etude de la variabilite genetique et fonctionnelle du vih et kit pour sa mise en oeuvre
ES2610781T3 (es) * 2004-09-14 2017-05-03 Argos Therapeutics, Inc. Amplificación de patógenos independiente de la cepa y vacunas para estos
US10113206B2 (en) * 2010-02-24 2018-10-30 Grifols Therapeutics Inc. Methods, compositions, and kits for determining human immunodeficiency virus (HIV)
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere

Also Published As

Publication number Publication date
ES2256855T3 (es) 2006-07-16
DE69635407T2 (de) 2006-08-03
EP0812359B1 (de) 2005-11-09
US6030769A (en) 2000-02-29
CA2214102A1 (fr) 1996-09-06
DE69635407D1 (de) 2005-12-15
EP0812359A1 (de) 1997-12-17
JPH11501805A (ja) 1999-02-16
WO1996027013A1 (fr) 1996-09-06
US6270975B1 (en) 2001-08-07
FR2731013B1 (fr) 1997-05-16
CA2214102C (fr) 2012-01-10
FR2731013A1 (fr) 1996-08-30

Similar Documents

Publication Publication Date Title
ATE309365T1 (de) Hiv-1 der gruppe 0, entsprechende fragmente dieses virus,sowie deren anwendungen
EP0675904A4 (de) Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch.
EP0724651A4 (de) Synthetische humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch
TR199800327T1 (en) A�ilaminosalisilamidler.
NO970221L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
DE60037450D1 (de) Funf-helix protein
DE69833160D1 (de) Amplifizierung und Detektion von HIV-1 und/oder HIV-2
BR9713388B1 (pt) processos de produÇço de vÍrus e de adenovÍrus recombinantes defectivos, e baculovÍrus recombinante.
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
ID23374A (id) Halogenopirimidin
TR199801418T2 (xx) Rekombinant a�� vekt�rleri kar���m�.
HN1996000017A (es) Isotiazolonas
EP0345462A3 (de) Immuntest für HIV-1-Antigene unter Benutzung von F(AB')2-Fragmenten als Sonde
EA200000196A1 (ru) Универсальная плазма крови
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
FI954699A0 (fi) MSRV1-virus ja multippeliskleroosiin liittyvä patogeeninen ja/tai infektoiva MSRV2-agenssi, niiden nukleiinihappokomponentteja ja niiden sovellutuksia
DK1100789T3 (da) Substituerede benzoylcyclohexandioner
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
BR9807936A (pt) Preparação farmacêutica imuno-tolerante de complexo de pró-trombina, processo para a produção de uma preparação, e, utilização de uma preparação
ATE138579T1 (de) Verwendung von enzymen
DK0946731T3 (da) Ikke-M, ikke O HIV-1 stammer, fragmenter og anvendelser
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
ATE469169T1 (de) Erythrovirus und ihre verwendung
ES2088464T3 (es) Uso y administracion de enzimas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties